BioSpace News Archive

Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing intranasal vaccines using a proprietary parainfluenza virus 5 (PIV5)-based vector, announced preliminary interim data today from a phase 1 clinical trial of its BLB201 vaccine for prevention of severe respiratory syncytial virus (RSV)-associated disease (NCT05281263).

Align Technology, Inc. announced the opening of its 2023 Research Award Program to support clinical and scientific dental research in universities across the globe.

Allarity Therapeutics, Inc. announced that the Company’s 2022 Annual Meeting of Stockholders, was convened on November 4, 2022, at 1:00 p.m. and was adjourned without any business being conducted.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, announced it will be participating in the Q4 Investor Summit Conference, which will take place on November 14, 2022 in New York, New York.

Recently, Scivita Medical Technology Co., Ltd. and FUJIFILM Europe B.V. headquartered in the Netherlands, jointly announced a strategic cooperation between the two companies.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November 14, 2022, at 8:00 a.m. EST to review business updates and its third quarter 2022 financial results.

Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, has presented positive preclinical data on three proteins identified by the FunSel platform which have potential to preserve heart function following a heart attack.

Tango Therapeutics, Inc. today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in November.

HOOKIPA Pharma Inc. today announced it will release its third quarter 2022 financial results and Company update before the market opens on Monday, November 14, 2022.

Nabriva Therapeutics plc today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022.